Allspring Global Investments’s Nurix Therapeutics NRIX Stock Holding History

Allspring Global Investments’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$336K	Buy	13,844 +434	+3%	+$7.39K	﹤0.01%	1549
2026 Q1	$208K	Buy	+13,410	New	+$222K	﹤0.01%	1602
2025 Q1	–	Sell	-89,920	Closed	-$1.69M	–	1791
2024 Q4	$1.69M	Sell	89,920 -50,353	-36%	-$1.15M	﹤0.01%	1181
2024 Q3	$3.15M	Buy	+140,273	New	+$3.18M	﹤0.01%	1059
2024 Q1	–	Sell	-1,018	Closed	-$10.5K	–	2369
2023 Q4	$10.5K	Sell	1,018 -217	-18%	-$1.49K	﹤0.01%	2019
2023 Q3	$9.71K	Sell	1,235 -4,029	-77%	-$36.8K	﹤0.01%	2611
2023 Q2	$52.6K	Buy	5,264 +4,036	+329%	+$41.2K	﹤0.01%	2280
2023 Q1	$10.9K	Buy	1,228 +327	+36%	+$3.41K	﹤0.01%	2587
2022 Q4	$9.89K	Sell	901 -20	-2%	-$241	﹤0.01%	2715
2022 Q3	$12K	Sell	921 -642	-41%	-$10.2K	﹤0.01%	2705
2022 Q2	$19K	Sell	1,563 -5,611	-78%	-$63.6K	﹤0.01%	2499
2022 Q1	$100K	Buy	7,174 +994	+16%	+$17.6K	﹤0.01%	2749
2021 Q4	$178K	Buy	+6,180	New	+$187K	﹤0.01%	2654

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Allspring Global Investments's NRIX Position: Q2 2026 in Review

Allspring Global Investments increased its Nurix Therapeutics (NRIX) stake by 3.2% in Q2 2026, buying an estimated $7.39K and bringing the position to 13,844 shares worth $336K. The position accounts for ﹤0.01% of the portfolio, ranked #1549.

Allspring Global Investments first reported a position in NRIX in Q4 2021 and has held it in 13 quarters since. The position peaked at $3.15M in Q3 2024. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Allspring Global Investments held 13,844 shares of Nurix Therapeutics worth $336K as of Q2 2026.
Allspring Global Investments bought 434 Nurix Therapeutics shares in Q2 2026, an estimated $7.39K.
Nurix Therapeutics made up ﹤0.01% of Allspring Global Investments's portfolio in Q2 2026, its #1549 holding.
Allspring Global Investments first reported a position in Nurix Therapeutics in Q4 2021 and has held it in 13 quarters since.
Allspring Global Investments's Nurix Therapeutics position peaked at $3.15M in Q3 2024.
211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Allspring Global Investments's 13F filing for Q2 2026, filed 13 Aug 2026.